CD8A and neoplasm: In addition, recent studies have identified leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) as a novel binding partner for VISTA that functions independently of pH, further contributing to CD8+ T cell dysfunction and tumor immune evasion [224].